Clinical trial
Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With…
NCT00445679 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00445679 |
|---|---|
| Title | Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD |
| Official title | A Multicenter, Randomized, Double-blind, Paroxetine-referenced, Parallel-group Study to Evaluate the Safety, Efficacy, and Tolerability of 3 Fixed Doses (50mg, 100mg, AND 200mg) of Desvenlafaxine Succinate Sustained-release Tablets in Adult Outpatients With Major Depressive Disorder |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Depressive Disorder, Major |
| Intervention type | Drug |
| Interventions | DVS SR, Paroxetine |
| Enrollment | 807 |
| Start date | Jul 1, 2007 |
| Primary completion | Feb 1, 2009 |
| Completion | Feb 1, 2009 |
| First posted | Mar 9, 2007 |
| Last update posted | Nov 4, 2013 |
| Countries | China, India, South Korea, Taiwan |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: